BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 18, 2025
Home » mTOR

Articles Tagged with ''mTOR''

Illustration of rapamycin inhibiting mTORC1
Cancer

SRRM2 drives colorectal cancer growth by a dual mTOR regulation

March 11, 2025
Scientists at Southern University of Science and Technology in Shenzhen, China, have identified a new regulator of the mammalian target of rapamycin (mTOR) pathway associated with the growth of colorectal cancer.
Read More
Neurology/psychiatric

Lipin-1 decline promotes axonal regeneration after spinal cord injury

Oct. 9, 2024
The central nervous system (CNS) in adult mammals has limited regeneration capacity, and traumatic injuries to the CNS usually lead to permanent functional impairment.
Read More
Brain scans

Kazia’s stock rockets on positive glioblastoma trial results

July 16, 2024
By Tamra Sami
Kazia Therapeutics Ltd.'s stock shot up 248% on July 10 after the Sydney-based company reported that paxalisib showed a 3.8-month improvement in overall survival, a 33% improvement, for newly diagnosed unmethylated patients with glioblastoma (GBM) compared to the concurrent standard-of-care arm in the pivotal GBM-Agile phase II/III study.
Read More
Brain scans

Kazia’s stock rockets on positive glioblastoma trial results

July 11, 2024
By Tamra Sami
Kazia Therapeutics Ltd.'s stock shot up 248% on July 10 after the Sydney-based company reported that paxalisib showed a 3.8-month improvement in overall survival, a 33% improvement, for newly diagnosed unmethylated patients with glioblastoma (GBM) compared to the concurrent standard-of-care arm in the pivotal GBM-Agile phase II/III study.
Read More
Respiratory

TREM-1 acts as a necroptotic stimulus of alveolar macrophages in acute lung injury

March 27, 2023
New research has shed light on a molecular mechanism that fuels inflammation in acute lung injury (ALI), a severe and often fatal condition. Macrophage necroptosis, a form of cell death, is a necessary process contributing to intrapulmonary inflammation during ALI. However, the molecular mechanism that initiates macrophage necroptosis has remained unclear until now.
Read More
3D rendering of alcohol dehydrogenase
Endocrine/Metabolic

Alcohol-metabolizing enzyme plays role in longevity

March 2, 2023
By Mar de Miguel
Scientists at the University of Virginia have discovered an anti-aging mechanism mediated by an enzyme that metabolizes alcohol. Alcohol dehydrogenase, which in Caenorhabditis elegans and yeast replaces the rejuvenating effect of autophagy, would reduce age-associated glycerol levels, also promoting longevity in mice and humans.
Read More
Malaria kinase inhibitors
Infection

Study uncovers antimalarial kinase inhibitors

Oct. 20, 2022
By Nuala Moran
Chemoproteomics studies have uncovered multiple potential kinase drug targets in the Plasmodium protozoan that causes malaria, and subsequent screening of approved kinase inhibitor drugs has now thrown up several hits with lethal activity at different stages of the complex life cycle of the parasite. Researchers at the University of Cape Town, South Africa, working with scientists at Glaxosmithkline plc, describe the activity in Plasmodium of one of these kinase inhibitors, the cancer drug sapanisertib, in a paper appearing in Science Translational Medicine, Oct. 19, 2022.
Read More
Drug Design, Drug Delivery & Technologies

Combination strategy enables brain-specific kinase inhibition

Sep. 15, 2022
By Anette Breindl
Using a two-drug combination, researchers at the University of California at San Francisco (UCSF) have been able to achieve brain-specific inhibition of several kinases.
Read More
Metformin

Extending the human lifespan: For preventing aging, some decades old drugs?

July 18, 2022
By Anette Breindl
The U.S. NIH’s National Institute on Aging’s Intervention Testing Program has been searching for ways to extend lifespan for more than two decades by now. And in its animal studies, it has been successful multiple times. There are half a dozen drugs, and a few lifestyle interventions, that reliably extend lifespan in one or both sexes by up to 30%. Read more in part four and five of BioWorld’s multipart series on extending the human lifespan.
Read More
T cells

TGF-beta-mediated mTOR inhibition preserves cellular metabolism of precursors of exhausted T cells

July 19, 2021
Scientists at the University of Melbourne and collaborators performed an in-depth metabolic characterization of precursors of exhausted (Tpex) cells in chronic lymphocytic choriomeningitis virus infection. Their results showed that Tpex metabolic attributes strongly contrast with those of exhausted effector (Tex) cells in the same environment.
Read More
Previous 1 2 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 18, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 18, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • GLP-1 capsule

    Maintenance, man: Lilly’s phase III weight trial hits goals

    BioWorld
    Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
  • Insilico CEO Alex Zhavoronkov and the automated lab’s humanoid that runs all preclinical tests in the Hong Kong lab.

    AI drug developer Insilico to raise $292 million in Hong Kong IPO

    BioWorld
    Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing